Mazdutide

How it works

Mazdutide copies oxyntomodulin: a GLP-1 arm to quiet hunger and steady insulin, and a glucagon arm to burn liver fat and raise energy use.

Sources

Read the original sources

The mechanism of action of oxyntomodulin in the regulation of obesity, Wynne 2010 (Abstract · checked 2026-10-13)
GLP-1, glucagon and the GLP-1/glucagon co-agonist oxyntomodulin after bariatric surgery, 2025, Diabetes Mellitus (Russia) (Summary · checked 2026-10-13)
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. (Ji · 2022 · Abstract; full methods not assumed · checked 2026-10-13)
Mazdutide: Chinese phase 3 trial (2025 · Published abstract · checked 2026-10-08)
Semaglutide lowers body weight in rodents via distributed neural pathways (2020 · Abstract; rodent mechanism · checked 2026-10-13)
Mazdutide eases fatty liver through ER stress, lipid metabolism and inflammation, Gan 2026, Pharmaceuticals (China) (Abstract · checked 2026-10-13)
Shared mechanistic pathways of glucagon signalling in obesity and fatty liver, Neff 2025, Diabetes Obes Metab (Abstract · checked 2026-10-13)